$GALT
Galectin Therapeutics Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · Norcross, GA
GALT chart
What traders are saying about $GALT
Latest postsGalectin Therapeutics Inc news
- Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - What's Next?
MarketBeat ·
- Galectin Therapeutics Inc. Estimates – NASDAQ:GALT
TradingView ·
- Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Yahoo Finance ·
- Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
Yahoo Finance ·
- Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Yahoo Finance ·
- GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
stocktwits.com ·
- Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Yahoo Finance ·
- Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Yahoo Finance ·
- Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Yahoo Finance ·
Galectin Therapeutics Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M |
| Diluted EPS | $-0.48 | $-0.76 | $-0.74 | $-0.65 |
| Total assets (year end) | $19.5M | $17.5M | $28.2M | $21.3M |
| Cash and equivalents (year end) | $17.7M | $15.1M | $25.7M | $18.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Galectin Therapeutics Inc
- Ticker
- GALT (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Norcross, GA
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 1133416
- Former names
- PRO PHARMACEUTICALS INC
Frequently asked questions
What exchange is Galectin Therapeutics Inc listed on?
Galectin Therapeutics Inc trades on the Nasdaq under the ticker symbol GALT.
What industry is Galectin Therapeutics Inc in?
Galectin Therapeutics Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Galectin Therapeutics Inc headquartered?
Galectin Therapeutics Inc's business address on file with the SEC is in Norcross, GA.
When does Galectin Therapeutics Inc's fiscal year end?
Galectin Therapeutics Inc's fiscal year ends on December 31.